Nickel-64 Market Size, Share, Growth, and Industry Analysis, By Type (Nickel-64 Metal, Nickel-64 Oxide), By Application (Biomedicine, Science Research), Regional Insights and Forecast to 2035

Nickel-64 Market Overview

Nickel-64 Market size is anticipated to be worth USD 67.23 million in 2026, projected to reach USD 271.84 million by 2035 at a 16.8% CAGR.

The Nickel-64 Market is gaining significant traction across isotope production, nuclear medicine research, radiopharmaceutical manufacturing, and advanced scientific applications due to the growing demand for enriched stable isotopes. Nickel-64 is primarily utilized in the production of Copper-64 radioisotopes, which are increasingly adopted in positron emission tomography imaging and targeted radionuclide therapies. More than 68% of enriched Nickel-64 demand is linked to medical isotope production facilities, while approximately 21% is associated with nuclear and energy-related research institutions. The purity level requirements for Nickel-64 exceed 99% in most medical-grade applications, creating strong demand for high-efficiency isotope separation technologies. Over 54% of global isotope laboratories have increased procurement volumes for enriched nickel isotopes due to expanding clinical trials involving Copper-64 diagnostics. The Nickel-64 Market Report indicates rising investments in cyclotron infrastructure, isotope enrichment technologies, and precision nuclear medicine capabilities, supporting long-term Nickel-64 Market Growth and Nickel-64 Industry Analysis.

The USA represents one of the most advanced regional markets for Nickel-64 isotope production and utilization due to the rapid expansion of nuclear medicine infrastructure and isotope research laboratories. Nearly 61% of domestic Nickel-64 consumption is associated with radiopharmaceutical production centers focused on Copper-64 synthesis. More than 48% of U.S.-based cyclotron facilities have expanded isotope handling capacities to support increasing demand for precision oncology imaging agents. Approximately 36% of isotope procurement contracts in the United States involve enriched Nickel-64 with purity levels above 99%. Research institutions and healthcare laboratories across the country continue to increase investments in stable isotope processing systems, while over 42% of ongoing radiopharmaceutical development programs utilize Nickel-64-derived isotopes for clinical applications. The Nickel-64 Market Outlook in the USA is also supported by expanding nuclear medicine adoption, higher PET scan volumes, and increasing partnerships between isotope manufacturers and biotechnology companies.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 68% of Nickel-64 utilization is connected to Copper-64 production, while over 52% of nuclear medicine laboratories reported increased isotope demand linked to precision oncology imaging applications and targeted radiopharmaceutical development programs.
• Major Market Restraint: Approximately 47% of isotope facilities face enrichment cost pressures, while nearly 39% of research organizations report limited access to high-purity Nickel-64 supply chains and advanced isotope separation infrastructure.
• Emerging Trends: Around 58% of radiopharmaceutical developers are integrating Copper-64 diagnostics into oncology pipelines, while 44% of isotope processing facilities are adopting automated enrichment technologies for improved isotope recovery efficiency.
• Regional Leadership: North America accounts for nearly 41% of advanced isotope production activities, while Europe contributes approximately 29% due to expanding radiopharmaceutical research and nuclear medicine infrastructure investments.
• Competitive Landscape: Nearly 34% of isotope suppliers are focusing on long-term medical isotope contracts, while 27% of producers are investing in ultra-high purity Nickel-64 refinement and isotope recycling technologies.
• Market Segmentation: Nickel-64 Metal contributes approximately 63% of industrial utilization, while Nickel-64 Oxide represents nearly 37% due to increasing application in isotope conversion and radiochemical processing systems.
• Recent Development: More than 46% of isotope manufacturers expanded enrichment capabilities, while 33% of medical isotope research facilities announced upgraded cyclotron installations supporting higher Copper-64 production efficiency.

Nickel-64 Market Latest Trends

The Nickel-64 Market Trends indicate substantial growth in medical isotope applications, particularly in oncology imaging and theranostic medicine. Approximately 62% of recent radiopharmaceutical development projects involve Copper-64 isotopes synthesized from enriched Nickel-64 targets. The growing adoption of positron emission tomography technologies has increased demand for high-purity isotope materials, with nearly 57% of diagnostic imaging centers reporting higher usage of isotope-based imaging compounds. Advanced isotope enrichment technologies have improved Nickel-64 recovery efficiency by approximately 31%, reducing isotope loss during production processes. More than 43% of nuclear medicine laboratories are integrating automated target processing systems to improve isotope handling safety and productivity. Additionally, around 38% of isotope suppliers are investing in recycling and purification systems to optimize enriched nickel utilization. The Nickel-64 Market Analysis also highlights rising collaborations between healthcare institutions and isotope manufacturers, particularly in North America and Europe. Nearly 49% of ongoing nuclear medicine clinical studies involve radioisotopes associated with targeted therapies, contributing to stronger Nickel-64 Industry Analysis and Nickel-64 Market Opportunities across healthcare and research sectors.

Nickel-64 Market Dynamics

DRIVER

"Rising demand for Copper-64 radiopharmaceutical production"

The primary growth driver in the Nickel-64 Market is the rapid increase in demand for Copper-64 radioisotopes used in advanced oncology imaging and targeted radionuclide therapies. More than 68% of Nickel-64 isotope utilization is associated with Copper-64 production processes. Approximately 59% of nuclear medicine facilities have increased isotope procurement volumes due to expanding positron emission tomography imaging requirements. Clinical research involving Copper-64 compounds has grown substantially, with nearly 46% of radiopharmaceutical pipelines now incorporating isotope-based diagnostic solutions. In addition, over 41% of healthcare institutions utilizing molecular imaging technologies reported increased dependence on enriched Nickel-64 targets for isotope synthesis. Technological improvements in cyclotron systems have enhanced isotope production efficiency by nearly 28%, supporting broader medical adoption. More than 37% of precision medicine initiatives globally involve radioisotope-supported diagnostic procedures. The Nickel-64 Market Research Report further identifies increasing government and institutional investments in nuclear medicine infrastructure, isotope handling systems, and medical imaging technologies as critical contributors to sustained market expansion and industrial demand growth.

RESTRAINTS

"Limited isotope enrichment infrastructure availability"

The Nickel-64 Market faces major restraints related to limited isotope enrichment capabilities and high production complexity. Approximately 47% of isotope manufacturers report operational constraints due to the limited number of advanced enrichment facilities capable of producing ultra-high purity Nickel-64. Enrichment processes for stable isotopes require highly specialized equipment, and nearly 35% of facilities encounter technical inefficiencies during isotope separation stages. In addition, over 39% of research laboratories experience delays in isotope procurement because of restricted production capacity and long enrichment cycles. The availability of qualified isotope processing experts remains another challenge, with approximately 26% of nuclear facilities reporting workforce shortages in radiochemical engineering operations. Transportation and handling regulations for enriched isotopes also impact operational efficiency, affecting around 31% of international supply chain activities. Furthermore, approximately 42% of isotope production facilities report elevated maintenance requirements associated with cyclotron systems and enrichment infrastructure. These operational limitations continue to affect production scalability, influencing overall Nickel-64 Market Forecast and supply consistency within the global isotope industry.

OPPORTUNITY

"Expansion of precision oncology and theranostic medicine"

The increasing adoption of precision oncology and theranostic medicine presents substantial opportunities within the Nickel-64 Market. More than 61% of advanced oncology diagnostic research programs now utilize isotope-assisted imaging technologies, creating strong demand for Nickel-64-derived Copper-64 radioisotopes. Approximately 53% of nuclear medicine developers are focusing on personalized cancer treatment solutions involving targeted radionuclide therapies. Clinical trials involving theranostic compounds have expanded significantly, with nearly 44% of recent isotope-based studies concentrating on combined diagnostic and therapeutic applications. Additionally, around 36% of biotechnology companies involved in radiopharmaceutical development have expanded isotope procurement partnerships to secure long-term Nickel-64 supplies. Advancements in automated isotope processing technologies have improved operational productivity by nearly 29%, increasing commercial viability for isotope manufacturers. Over 33% of healthcare systems globally are investing in nuclear medicine infrastructure modernization programs, supporting future isotope demand growth. The Nickel-64 Market Opportunities are also strengthened by increasing collaborations between academic research centers, healthcare institutions, and radiopharmaceutical manufacturers seeking enhanced isotope availability and improved patient-specific diagnostic capabilities.

CHALLENGE

"High production complexity and purification requirements"

The Nickel-64 Market faces considerable challenges associated with complex production procedures and strict isotope purity standards. Nearly 52% of isotope processing facilities report difficulties maintaining purity levels exceeding 99% during enrichment and conversion stages. Advanced separation systems require highly controlled operational environments, and approximately 38% of producers encounter efficiency losses during purification cycles. The technical complexity of cyclotron-based isotope production contributes to elevated operational risks, affecting around 34% of isotope manufacturing projects. In addition, over 27% of nuclear medicine laboratories report limitations related to isotope shelf-life management and radiochemical stability during transportation and storage. The installation and maintenance of isotope enrichment infrastructure remain technically demanding, with approximately 31% of facilities facing delays related to system calibration and equipment validation procedures. Global regulatory compliance requirements for isotope production and radiopharmaceutical applications continue to evolve, impacting around 29% of international supply chain operations. These technical and operational challenges remain critical factors influencing the broader Nickel-64 Industry Report and long-term production scalability.

Nickel-64 Market Segmentation

The Nickel-64 Market is segmented based on type and application, with increasing adoption across medical isotope production, nuclear medicine research, and radiochemical processing industries. Nickel-64 Metal accounts for a significant proportion of isotope target manufacturing due to its high enrichment compatibility and cyclotron efficiency. Nickel-64 Oxide is widely utilized in isotope conversion and radiochemical synthesis applications. More than 64% of overall demand originates from medical isotope production activities, while approximately 24% is linked to academic and nuclear research institutions. The Nickel-64 Market Insights indicate growing diversification of isotope applications across advanced diagnostic technologies and precision medicine programs.

Download FREE Sample to learn more about this report.

BY TYPE

Nickel-64 Metal: Nickel-64 Metal represents the dominant product category within the Nickel-64 Market due to its extensive utilization in cyclotron target manufacturing and radioisotope production systems. Approximately 63% of enriched Nickel-64 demand is associated with metallic target fabrication processes used in Copper-64 synthesis. High-purity Nickel-64 metal with enrichment levels above 99% is increasingly preferred across nuclear medicine facilities because of its improved irradiation efficiency and lower impurity generation during isotope production. Nearly 48% of medical isotope manufacturers prioritize metallic Nickel-64 targets for advanced positron emission tomography applications. The adoption of precision machining technologies has improved target fabrication efficiency by approximately 26%, supporting enhanced isotope output stability. In addition, around 39% of isotope production laboratories are investing in advanced metallic target recycling systems to improve operational sustainability and reduce isotope material losses. Nickel-64 Metal is also gaining traction in research reactors and particle accelerator facilities, where approximately 32% of isotope development programs utilize metallic nickel targets for experimental radiochemical applications. The Nickel-64 Market Analysis indicates strong future demand for metallic isotope materials due to expanding nuclear medicine infrastructure and increasing adoption of targeted radionuclide therapies.

Nickel-64 Oxide: Nickel-64 Oxide is increasingly utilized in radiochemical conversion processes, isotope synthesis systems, and specialized nuclear research applications. Approximately 37% of Nickel-64 processing activities involve oxide-based compounds due to their compatibility with specific radiochemical extraction and purification procedures. Around 42% of isotope laboratories utilize Nickel-64 Oxide during intermediate conversion stages associated with Copper-64 production workflows. The material demonstrates high thermal stability and improved chemical handling properties, making it suitable for advanced isotope preparation systems. Nearly 34% of radiopharmaceutical research organizations prefer oxide-based isotope materials for laboratory-scale synthesis operations and isotope development testing. Furthermore, approximately 28% of nuclear chemistry facilities have integrated automated oxide processing technologies to improve purification efficiency and minimize contamination risks. Nickel-64 Oxide is also widely adopted in research involving radiometal labeling compounds, with nearly 31% of experimental isotope studies utilizing oxide-derived precursor materials. Increasing investments in radiochemical infrastructure and isotope purification technologies continue to strengthen demand for Nickel-64 Oxide across medical research institutions and advanced nuclear science applications, contributing significantly to overall Nickel-64 Market Growth and Nickel-64 Industry Analysis.

BY APPLICATION

Biomedicine: The biomedicine segment dominates the Nickel-64 Market due to the extensive utilization of enriched Nickel-64 in the production of Copper-64 radioisotopes for oncology diagnostics and targeted radionuclide therapy. More than 71% of total Nickel-64 consumption is associated with biomedical isotope manufacturing processes. Approximately 64% of positron emission tomography imaging centers involved in advanced cancer diagnostics rely on Copper-64 generated from enriched Nickel-64 targets. In nuclear medicine laboratories, over 58% of isotope synthesis procedures utilize Nickel-64 because of its high isotopic purity and efficient irradiation properties. The growing adoption of precision medicine technologies has increased the use of Copper-64-labeled compounds by nearly 46% across clinical oncology applications. Around 39% of radiopharmaceutical developers are expanding production capacities for Copper-64 tracers to support personalized diagnostic programs. In addition, nearly 34% of healthcare research facilities are integrating automated isotope purification systems to improve isotope recovery efficiency and reduce contamination levels. Nickel-64-based biomedical applications are also increasing in neurological imaging and cardiovascular diagnostics, where approximately 27% of isotope-assisted imaging studies now involve Copper-64 radiotracers. The Nickel-64 Market Research Report indicates that continuous advancements in theranostic medicine, molecular imaging technologies, and radiopharmaceutical innovation are accelerating biomedical demand for enriched Nickel-64 isotopes globally.

Science Research: The science research application segment represents a substantial portion of the Nickel-64 Market due to growing utilization across nuclear chemistry, particle physics, radiochemical analysis, and isotope behavior studies. Approximately 43% of global isotope research facilities actively use Nickel-64 in experimental nuclear science programs and advanced radiochemical investigations. More than 36% of academic laboratories conducting stable isotope experiments depend on high-purity Nickel-64 for controlled irradiation and isotope transformation analysis. In particle accelerator facilities, nearly 31% of isotope development projects involve Nickel-64 targets for testing nuclear reaction pathways and isotope production efficiency. Research institutions focusing on radiometal chemistry have increased Nickel-64 procurement volumes by approximately 29% to support isotope labeling and tracer studies. Furthermore, around 26% of government-funded nuclear science initiatives involve stable nickel isotopes for material characterization and advanced spectroscopy applications. The adoption of automated isotope separation technologies has improved laboratory productivity by nearly 22%, enabling more precise isotope analysis and enhanced radiochemical experimentation. Approximately 33% of nuclear research reactors globally conduct periodic experiments involving Nickel-64-derived isotopes for medical and industrial research purposes. The Nickel-64 Industry Analysis highlights strong future demand from scientific institutions pursuing innovations in isotope science, nuclear engineering, and radiopharmaceutical development.

Nickel-64 Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America remains the leading regional market within the Nickel-64 Market due to advanced nuclear medicine infrastructure, high radiopharmaceutical adoption rates, and extensive isotope production capabilities. Approximately 41% of global Nickel-64 utilization originates from North American medical isotope facilities. More than 62% of regional demand is associated with Copper-64 production for oncology imaging and targeted radionuclide therapy. Around 48% of nuclear medicine centers across the region have expanded isotope handling systems to support increased PET imaging volumes. In addition, approximately 37% of isotope research projects conducted in North America involve stable nickel isotope applications. Advanced cyclotron installations have increased isotope production efficiency by nearly 29%, while over 34% of radiopharmaceutical developers are investing in automated purification systems. Nearly 31% of healthcare institutions are expanding molecular imaging capabilities involving Copper-64 diagnostic agents. Research collaborations between isotope laboratories and biotechnology companies continue to increase, with approximately 27% of regional isotope development programs focusing on precision oncology solutions. The Nickel-64 Market Outlook for North America remains strong due to rising investments in nuclear medicine infrastructure and isotope enrichment technologies.

Europe

Europe represents a major contributor to the Nickel-64 Market due to increasing investments in radiopharmaceutical innovation, nuclear science infrastructure, and advanced isotope research programs. Approximately 29% of global enriched Nickel-64 processing activities are conducted across European isotope laboratories and medical research institutions. More than 54% of regional demand is linked to radiopharmaceutical manufacturing and Copper-64 synthesis operations. Around 43% of healthcare research centers in Europe are involved in theranostic medicine studies utilizing Nickel-64-derived isotopes. The adoption of advanced isotope purification systems has improved radiochemical processing efficiency by nearly 26% throughout the region. Furthermore, approximately 35% of nuclear medicine facilities have upgraded cyclotron systems to support expanded radioisotope production capabilities. Over 32% of isotope-related clinical studies focus on personalized cancer diagnostics and targeted therapy applications. Europe also demonstrates strong scientific research activity, with nearly 28% of academic nuclear chemistry projects involving stable nickel isotopes for advanced experimentation. Increasing partnerships between research organizations and isotope manufacturers continue to strengthen the regional supply chain, while approximately 24% of isotope facilities are implementing recycling technologies to improve material sustainability and isotope utilization efficiency.

Asia-Pacific

The Asia-Pacific region is experiencing significant expansion in the Nickel-64 Market due to growing nuclear medicine adoption, increasing healthcare modernization, and expanding isotope research activities. Approximately 24% of global Nickel-64 demand is generated across Asia-Pacific healthcare and research institutions. More than 46% of regional radiopharmaceutical facilities have increased isotope procurement volumes to support rising diagnostic imaging requirements. Around 38% of newly installed cyclotron systems in the region are designed to support advanced isotope production, including Copper-64 synthesis from enriched Nickel-64 targets. In addition, approximately 33% of biotechnology research programs in Asia-Pacific involve isotope-assisted molecular imaging applications. Nuclear medicine adoption rates have increased substantially, with nearly 41% of advanced oncology imaging centers integrating isotope-based diagnostic technologies. Research laboratories involved in radiochemical development have expanded isotope handling capacities by approximately 27% to support scientific experimentation and clinical research. Furthermore, around 22% of regional isotope manufacturers are investing in automated enrichment and purification systems to improve production efficiency. The Nickel-64 Market Forecast for Asia-Pacific remains positive due to increasing healthcare infrastructure development, rising demand for precision medicine technologies, and expanding investments in isotope production capabilities.

Middle East & Africa

The Middle East & Africa region is gradually strengthening its position in the Nickel-64 Market due to increasing investments in nuclear medicine infrastructure, healthcare modernization programs, and scientific research initiatives. Approximately 11% of regional healthcare institutions have integrated advanced isotope-assisted diagnostic systems involving Copper-64 imaging compounds. Around 23% of nuclear medicine centers are expanding radiopharmaceutical capabilities to improve oncology diagnostics and precision treatment solutions. In addition, nearly 19% of regional isotope procurement activities are linked to medical imaging applications involving enriched Nickel-64. Research collaborations between healthcare facilities and academic institutions have increased by approximately 16%, supporting advancements in nuclear science and isotope utilization. More than 21% of newly established radiochemistry laboratories in the region are implementing isotope purification systems for medical and research applications. Furthermore, approximately 18% of regional nuclear science programs involve stable isotope experimentation related to radiopharmaceutical development and material analysis. Investments in healthcare technology infrastructure continue to rise, while nearly 14% of medical imaging facilities are upgrading cyclotron and isotope handling equipment. The Nickel-64 Industry Report indicates that the region is witnessing gradual expansion in isotope utilization due to growing awareness of nuclear medicine technologies and increasing healthcare innovation activities.

List of Key Nickel-64 Market Companies

• Rosatom
• Brookhaven National Laboratory
• Lawrence Berkeley National Laboratory
• Cambridge Isotope Laboratories
• BuyIsotope
• American Elements
• Trace Sciences
• CortecNet

Top Companies with Highest Market Share

• Rosatom: Approximately 24% of enriched isotope production activities in the Nickel-64 Market are associated with Rosatom due to its advanced isotope separation infrastructure, high-capacity nuclear processing systems, and strong involvement in medical isotope supply programs supporting radiopharmaceutical manufacturing and nuclear medicine applications.
• Cambridge Isotope Laboratories: Nearly 19% of specialized stable isotope distribution activities involve Cambridge Isotope Laboratories because of its broad isotope portfolio, advanced purification capabilities, and strong supply relationships with biotechnology companies, research laboratories, and radiopharmaceutical development institutions.

Investment Analysis and Opportunities

The Nickel-64 Market is attracting substantial investments due to rising demand for nuclear medicine isotopes, precision oncology technologies, and advanced radiopharmaceutical applications. Approximately 46% of isotope manufacturers are increasing investments in enrichment infrastructure and automated isotope separation systems. More than 39% of nuclear medicine laboratories are allocating higher capital expenditure toward cyclotron modernization and isotope handling technologies. Investment activity associated with Copper-64 production has increased significantly, with nearly 52% of radiopharmaceutical developers expanding isotope procurement partnerships to secure stable Nickel-64 supply chains. In addition, around 34% of biotechnology firms are funding research programs involving targeted radionuclide therapies and isotope-assisted molecular imaging systems. Scientific institutions are also strengthening investment activities, with approximately 28% of nuclear research facilities adopting advanced radiochemical purification technologies. Furthermore, over 31% of healthcare organizations are increasing investments in positron emission tomography imaging infrastructure involving isotope-based diagnostics. The Nickel-64 Market Opportunities continue to expand through advancements in theranostic medicine, personalized oncology treatment systems, and isotope recycling technologies that improve operational sustainability and production efficiency.

New Products Development

The Nickel-64 Market is witnessing continuous innovation in isotope enrichment technologies, radiochemical purification systems, and advanced radiopharmaceutical development. Approximately 44% of isotope producers are introducing next-generation Nickel-64 enrichment methods designed to improve isotope purity levels above 99%. More than 37% of radiopharmaceutical manufacturers are developing advanced Copper-64 compounds for precision oncology diagnostics and targeted therapy applications. Automated target processing systems capable of reducing isotope loss by nearly 26% are increasingly being adopted across isotope laboratories. In addition, around 32% of nuclear medicine developers are focusing on integrated isotope handling solutions that enhance radiochemical safety and operational productivity. New isotope recycling technologies have improved material recovery efficiency by approximately 29%, supporting sustainable isotope manufacturing practices. Approximately 24% of biotechnology research programs are developing innovative Copper-64-based tracers for neurological imaging and cardiovascular diagnostics. Furthermore, over 21% of isotope research facilities are introducing compact purification modules to improve laboratory-scale isotope synthesis. These product innovations continue to strengthen Nickel-64 Market Growth and support expanding applications in healthcare and nuclear science sectors.

Five Recent Developments(2023-2025)

• Advanced Cyclotron Expansion: In 2024, approximately 33% of isotope manufacturing facilities expanded cyclotron capacities to support increased Copper-64 production from enriched Nickel-64 targets. The upgrades improved irradiation efficiency by nearly 24% and reduced isotope processing downtime by approximately 18%, supporting stronger radiopharmaceutical supply capabilities.
• Radiopharmaceutical Collaboration Programs: During 2024, nearly 29% of biotechnology companies entered strategic collaborations with isotope suppliers to secure long-term Nickel-64 availability for oncology imaging applications. These partnerships improved isotope procurement stability and increased production coordination efficiency by approximately 22% across participating facilities.
• Automated Purification Technology Integration: In 2025, around 31% of nuclear medicine laboratories implemented automated purification systems for Nickel-64-derived isotope processing. These systems improved radiochemical purity control by approximately 27% and reduced contamination risks during isotope conversion procedures by nearly 19%.
• Expansion of Precision Oncology Research: Approximately 41% of ongoing radiopharmaceutical clinical studies in 2024 involved Copper-64 compounds synthesized from Nickel-64 targets. Increased clinical adoption contributed to nearly 26% higher demand for enriched Nickel-64 materials among medical research institutions and diagnostic imaging developers.
• Isotope Recycling Technology Development: In 2025, nearly 23% of isotope production facilities adopted advanced Nickel-64 recycling systems designed to improve enriched material recovery efficiency. The technology reduced isotope wastage by approximately 21% while enhancing operational sustainability across radiopharmaceutical manufacturing environments.

Report Coverage Of Nickel-64 Market

The Nickel-64 Market Report provides comprehensive analysis of isotope production technologies, radiopharmaceutical applications, enrichment infrastructure, and nuclear medicine developments influencing global market expansion. The report evaluates more than 68% of demand originating from medical isotope production facilities and highlights increasing adoption of Copper-64 radiotracers for precision oncology diagnostics. Approximately 47% of analyzed facilities reported increased investments in isotope purification systems and automated radiochemical processing technologies. The report also examines isotope utilization trends across scientific research institutions, nuclear chemistry laboratories, and biotechnology development programs.

In addition, the Nickel-64 Industry Report covers regional isoto